Mainz Biomed (MYNZ) - Prakiraan wutah bathi saben saham kanggo taun ngarep

Mainz Biomed N.V. (MYNZ) - logo korporat

Mainz Biomed N.V. is developing non-invasive colorectal cancer diagnostics, diversifying across US and European markets. The forward EPS forecast for the coming year is derived from the GURU.Markets chart, where 98.70 represents the current metric. This confirms the company's ESG status by reducing bio-waste and strictly adhering to medical regulations regarding chemical disposal in laboratories.

mainzbiomed.com (MYNZ): Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep saka 04.07.2022 nganti 11.03.2026

MYNZ (Mainz Biomed NV): rincian analitis lan laporan miturut indikator

- rega lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:mainzbiomed.com, MYNZ
Barang utama Mainz Biomed

The positive trend in the forward net income growth rate reflects market confidence in the commercialization of Mainz Biomed N.V. (MYNZ) non-invasive tests in Europe and the US. This indicator measures the percentage change in expected earnings per share (EPS) for the following year, allowing investors to assess the fundamental resilience of the business and adjust their entry strategy for the asset in a timely manner.